Sign up for free insights newsletter
60

Humanwell Healthcare Group Co Ltd

600079SHG

Need professional-grade analysis? Visit stockanalysis.com

CN¥18.80
-0.95%
End of day
Market Cap

$30.65B

P/E Ratio

16.47

Employees

17,650

Dividend Yield

2.53%

Price Chart

Risk-Adjusted Performance

Ratio1W1M3M6M1Y5YScore
Sortino12.294.99-1.00-0.591.28
Calmar17.42-0.89-0.382.67
Sharpe5.432.89-0.72-0.380.54
Omega2.491.540.870.951.15
Martin30.22-1.49-0.744.61
Ulcer0.471.6011.9612.699.58

Humanwell Healthcare Group Co Ltd (600079) Price Performance

Humanwell Healthcare Group Co Ltd (600079) trades on SHG in CNY. The company is classified in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. The stock currently trades at CNY18.80, down 0.95% from the previous close.

Over the past year, 600079 has traded between a low of CNY17.24 and a high of CNY23.03. The stock has lost 9.8% over this period. It is currently 18.4% below its 52-week high.

Humanwell Healthcare Group Co Ltd has a market capitalization of $30.65B, with a price-to-earnings ratio of 16.47 and a dividend yield of 2.53%.

About Humanwell Healthcare Group Co Ltd

Humanwell Healthcare (Group) Co.,Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers sufentanil citrate injection, an analgesic drug for combined anesthesia; remifentanil hydrochloride injection for induction of general anesthesia and maintenance of analgesia during general anesthesia; hydromorphone hydrochloride injection for patients who require opioid analgesia; nabuphine hydrochloride injection for use as an analgesic for anesthesia induction; alfentanil hydrochloride injection, a narcotic analgesic; remizaren besylate injection for sedation and anesthesia during non-endotracheal intubation surgery; and mifepristone preparations for pregnancy prevention or termination. It also provides zuka wood particles for colds; compound muniziqi granules to treat skin and gynecologicalconditions; urokinase injection for thromboembolic diseases; and neomycin sulfate API for the prevention and treatment of intestinal diseases in animals. In addition, the company offers progesterone, estrogen, androgen, cortical hormone, and other API products; steroid hormone products; natural plant-based medicines; central nervous system drugs; animal medicine; narcotics; and Uyghur medicine products. Further, it is involved in the production of veterinary drugs, feed additive, medical devices, and agricultural products; technical development, exchange, and transfer; leasing of medical devices; conference, exhibition, inspection, and testing; property management; pharmaceutical contract manufacturing; cleaning, washing, and disinfection; warehousing and logistics; investment management and consulting services; and production of health foods. The company was formerly known as Wuhan Humanwell Healthcare (Group) Co., Ltd. and changed its name to Humanwell Healthcare (Group) Co.,Ltd. in March 2013. Humanwell Healthcare (Group) Co.,Ltd. was founded in 1988 and is based in Wuhan, China.

Compare Humanwell Healthcare Group Co Ltd

Side-by-side comparison against top Healthcare peers.

Company Info

Exchange
SHG
Currency
CNY
Country
China

Financial Metrics

Revenue (TTM)
$23.96B
EBITDA
$4.55B
Profit Margin
7.74%
EPS (TTM)
1.14
Book Value
11.59

Technical Indicators

52 Week High
CN¥23.66
52 Week Low
CN¥16.73
50 Day MA
CN¥19.07
200 Day MA
CN¥19.98
Beta
0.51

Valuation

Trailing P/E
16.47
Forward P/E
26.39
Price/Sales
1.28
Price/Book
1.64
Enterprise Value
$34.59B